BASEL, Switzerland, May 31 /PRNewswire/ --
- Thousands Of Patients Benefit Provided From Avastin-Based Therapy
A wealth of new Avastin (bevacizumab) data will be presented at the
44th annual meeting of the American Society of Clinical Oncology (ASCO) in
Chicago confirming that Avastin-based therapy is essential for patients
with metastatic colorectal cancer (CRC). In total 15 separate data
presentations will be made with highlights including:
1. Overall survival data confirmed in two large community-based studies,
including some 4,000 patients
2. First full data presentation of an Avastin and cetuximab combination
3. Impressive rates of curative surgery following treatment with Avastin
4. Survival benefits of Avastin confirmed with yet another chemotherapy
1. Long-term overall survival reported by studies including almost 4,000 patients
The long-term benefits of Avastin use in combination with chemotherapy were confirmed by two large studies, which collectively included almost 4,000 patients with metastatic CRC. Key findings presented at ASCO from the First BEAT and BRiTE studies, which paired Avastin with chemotherapy of the investigator's choice, were:
- Avastin-based therapy provides a median overall survival benefit for patients of approximately two years (24.5 and 22.7 months from BRiTE and First BEAT respectively).
- Importantly, long-term Avastin exposure did not increase the risk of the patient suffering from Avastin-specific side effects. The incidence of Avastin-specific side effects were consistent with those reported in other scientific studies and were even less after one year of treatment.
2. Adding cetuximab to Avastin and chemotherapy decreases the time patients live without their disease getting worse
The first data presentation from the 755 patient CAIRO-2 study, which
compared Avastin + chemo
Copyright©2008 PR Newswire.
All rights reserved